News and Trends 11 Oct 2018 Rechargeable Dentures Could Prevent Mouth Infections As well as helping you chew your hamburger, dentures could one day fight oral fungal infections, suggest researchers from Manchester Metropolitan University, UK. The population is getting older. In fact, it is predicted that almost half of Europe will be over 50 years old in the year 2050. Assuming that trends stay the same, this […] October 11, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2018 Cancer Immunotherapy Phase I on Hold After Patient Death The German biotech Affimed has halted two Phase I trials of its cancer immunotherapy after three patients suffered neurotoxicity due to the treatment, causing the death of one of them. Affimed was testing its immunotherapy AFM11 in 33 patients diagnosed with white blood cell cancer in two Phase I trials. One trial tested the therapy […] October 10, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Oct 2018 Slow-Release Drug Biotech IPO Raises €30M The French biotech MedinCell, an injectable slow-release drug specialist, has received a shot of success as its IPO raises €30M in the Euronext stock exchange in Paris. MedinCell is hoping to improve patient compliance with medication regimes by injecting them with a drug-infused gel. Patient compliance with taking medication can be as low as 30% […] October 9, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Oct 2018 Hormone Therapy for Inherited Hormonal Disorder Fails at Phase III A European Phase III trial has become a major stress for British biotech Diurnal. Its specially designed hormone therapy was no better than conventional therapies in treating an inherited hormonal disorder. Congenital adrenal hyperplasia is a rare genetic condition where patients lack crucial enzymes for making hormones. The most common form lacks 21-hydroxylase, the enzyme […] October 9, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2018 Oxford Biotech Launches with €26M to Target ‘Immunometabolism’ Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […] October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2018 Lab-Grown Antivenom Shows Potential for Curing Black Mamba Snakebite Antivenoms could one day be made in the lab instead of in animals. Researchers from the Technical University of Denmark have neutralized black mamba venom in mice with lab-grown human antibodies for the first time. Snakebite is a serious problem, causing the deaths of around 100,000 people every year, and about three times that number […] October 5, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2018 This Year’s Nobel Prizes Highlight Advances in Biotechnology Immune system brakes, optical tweezers, and enzyme evolution. Three separate subjects that span this year’s Nobel Prizes in Physiology or Medicine, Physics and Chemistry. Despite the differences in theory, however, the diverse discoveries have one thing in common: they have applications in the biotechnology industry, Labiotech’s favorite subject. Releasing the immune system’s brakes in cancer […] October 4, 2018 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2018 Algorithm Proves Better Than Humans at Controlling Blood Sugar in Type 1 Diabetes A clinical trial has shown that letting an algorithm decide the amount of insulin a person with type 1 diabetes needs can help keep blood sugar levels under control. The algorithm, being developed at the University of Cambridge, is able to predict how much insulin is needed at each point in time based on the […] October 3, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2018 Septic Shock Drug Shows Promise for Personalized Medicine Septic shock may no longer be as shocking in the future, as a Phase IIa trial brings hope for a personalized immunomodulatory treatment from the French biotech Inotrem. In sepsis, the immune system overreacts to the infection of a pathogen, causing uncontrolled inflammation throughout the body and organ failure. This can lead to septic […] October 2, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2018 Update: Forbion’s Life Science Fund Tops Goal by €90M Update: The European venture capital firm Forbion closed fundraising for it’s fourth life sciences fund at €360M, a much greater amount than the anticipated €250M. The oversubscribed fund is great news for European medical biotech companies, which will be a strong focus for the fund, and shows that there is a strong interest in the […] October 1, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2018 Cancer-Sniffing Diagnostics Company Secures €43.1M Funding Intoxication is not the only condition that we could diagnose with breathalyzers. The UK-US company Owlstone Medical has secured €43.1M funding to help commercialize its tech that ‘smells’ cancer in your breath. Owlstone’s breathalyzer kit diagnoses conditions by measuring volatile organic compounds in a person’s breath. Disease pathologies affect the types and amounts of these […] October 1, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2018 Roche Acquires UK Cancer Immunotherapy Biotech in Deal Worth up to €655M Tusk Therapeutics has been acquired by Swiss pharma giant Roche, which aims to develop one of its lead immunological cancer treatments. Roche has given Tusk’s shareholders €70M upfront, with up to an additional €585M planned if Tusk achieves certain milestones. Roche seems particularly interested in one of Tusk’s lead programs, an antibody that reduces the […] September 28, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email